HTC Assessment and Initial Course of Action

• Comprehensive care visit and examination at the HTC yields evidence of arthropathy in both of Reggie's knees
• Laboratory testing reveals that he has again developed an inhibitor since discontinuing prophylaxis at age 18
• According to the results of a Bethesda assay, the titer of the inhibitor is determined to be 30 BU
• ITI was once again attempted with rFVIII, with on-demand rFVIIa used for bleeding episodes while resuming ITI

 

Mark T. Reding, MD Associate Professor of Medicine Director, Center for Bleeding and Clotting Disorders University of Minnesota Medical Center